Pain management testing services
The use of controlled substances to manage pain is widely accepted by health care professionals, but these prescriptions correlate with an increased risk for drug abuse and overdose. Because as many as one in four patients on long-term, controlled substance therapy struggles with addiction, objective measures are needed to identify recent drug use and evaluate for misuse.
Our patient-centric approach to controlled substance monitoring is backed by more than 150 years of medical knowledge and developed by an award-winning team of pain medicine, primary care, and addiction experts who work collaboratively with the Clinical and Forensic Toxicology Laboratory at Mayo Clinic. Our tests are based on practice guidelines developed by the American Association for Clinical Chemistry Academy, and provide clinicians with assistance to ensure patients who receive controlled substance therapy remain within regulatory parameters.
By the numbers
lab-developed therapeutic tests available
Our liquid chromatography-tandem mass spectrometry, high-resolution accurate mass (LC-MS/MS HRAM) screens, and confirmatory testing for identification and monitoring controlled substances are available based on the needs of your patients and laboratory.
Please note: If the limited immunoassay screen is positive in this profile (Mayo ID: CSMPU), confirmation with quantification of presumptive positives for barbiturates, cocaine and metabolites, and/or tetrahydrocannabinol metabolite will be performed at an additional charge. If the quantification of presumptive positive results is not required, refer to Controlled Substance Monitoring Hybrid Drug Profile, High-Resolution Mass Spectrometry, and Immunoassay Screen, Random, Urine (Mayo ID: CSMHU)
*To better meet the needs of our clients’, this profile is available with the quantification of presumptive positive results (Mayo Test ID: CSMPU) or without (Mayo Test ID: CSMHU) for the drug classes screened by immunoassay (i.e., barbiturates, cocaine, and THC).
**Ethyl glucuronide (EtG) and ethyl sulfate (EtS) are direct biomarkers of ethanol and are detectable in urine for up to five days following alcohol consumption. EtG/EtS results should be interpreted in the context of all available clinical and behavioral information.
Learn more about how to order these tests at your institution.